PCN127 What Is the IMPACT of the Introduction of Ipilimumab, Pembrolizumab, and Nivolumab on Malignant Melanoma in Nordics?

2021 ◽  
Vol 24 ◽  
pp. S42
Author(s):  
G. Mangat ◽  
S. Sharma
Keyword(s):  
Malignant Melanoma ◽  
The Impact

The impact of immunohistochemistry on sentinel node biopsy for primary cutaneous malignant melanoma

2003 ◽  
Vol 56 (2) ◽  
pp. 153-155 ◽  
Author(s):  
G.L. Ross ◽  
T. Shoaib ◽  
J. Scott ◽  
I.G. Camilleri ◽  
H.W. Gray ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Cutaneous Malignant Melanoma ◽  
Primary Cutaneous Malignant Melanoma ◽  
Node Biopsy ◽  
The Impact

scholarly journals Assessment of the perceived burden associated with Malignant Melanoma with Pictorial Representation of Illness and Self Measure (PRISM) and Melanoma Concerns Questionnaire (MCQ-28)

2022 ◽  
Author(s):  
Alessandro Borghi ◽  
Maria Elena Flacco ◽  
Alberto Monti ◽  
Lucrezia Pacetti ◽  
Michela Tabanelli ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Well Being ◽  
Cross Sectional Study ◽  
Pictorial Representation ◽  
Cross Sectional ◽  
Prism Score ◽  
Related Data ◽  
Perceived Burden ◽  
Study Population ◽  
The Impact

Abstract Purpose The impact of malignant melanoma (MM) on patients’ psychophysical well-being has been poorly addressed. We aimed to assess the perceived burden in patients with a diagnosis of MM, using two different tools, one generic and one specific for MM, such as Pictorial Representation of Illness and Self Measure (PRISM) and Melanoma Concerns Questionnaire (MCQ-28), respectively. The correlation between PRISM and MCQ-28 subscales and the relevance of disease and patient-related variables were also investigated. Methods This single-centre, cross-sectional study included all adult consecutive MM patients who attended our Dermatology Unit from December 2020 to June 2021. Demographics and disease-related data were recorded. PRISM and MCQ-28 were administered. Results One hundred and seventy-one patients were included (mean age: 59.5 ±14.9 years.; 48.0% males). Median time from MM diagnosis to inclusion was 36 months. Nearly 80% of the patients had in situ or stage I MM. Overall, 22.2% of the patients reported a PRISM score <100mm and similar percentages provided scores indicating impaired quality of life, as assessed with MCQ-28 subscales. A weak, albeit significant, correlation was found between PRISM scores and ACP, CON and SOC2 subscales. The most relevant association found was that between lower PRISM scores and higher-stage MM. Conclusions In the study population, mostly affected with superficial MM, their perception of the burden associated with MM did not appear either particularly dramatic or disabling. PRISM seems a reliable system for capturing and quantifying the domains correlated with the emotive dimension of MM, especially MM-related concerns and willingness to face life

The impact of sequencing on diagnosis and treatment of malignant melanoma

2016 ◽  
Vol 16 (4) ◽  
pp. 423-433 ◽  
Author(s):  
Roberta Castiglione ◽  
Michaela A. Ihle ◽  
Carina Heydt ◽  
Anne M. Schultheis ◽  
Sabine Merkelbach-Bruse ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Diagnosis And Treatment ◽  
The Impact

scholarly journals Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters

2019 ◽  
Vol 56 (6) ◽  
pp. 1104-1109 ◽  
Author(s):  
Jan Viehof ◽  
Elisabeth Livingstone ◽  
Elena Loscha ◽  
Paul Stockhammer ◽  
Agnes Bankfalvi ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Malignant Melanoma ◽  
Treatment Options ◽  
Pulmonary Metastasectomy ◽  
Long Term Outcome ◽  
Female Patients ◽  
Novel Treatment ◽  
The Impact

AbstractOBJECTIVESPulmonary metastasectomy for malignant melanoma requires an individualized therapeutic decision. Due to recently developed novel treatment options, the prognosis of patients with melanoma has improved significantly. Validated prognostic factors that identify patients who are most likely to benefit from metastasectomy are urgently needed.METHODSWe retrospectively reviewed all consecutive patients with melanoma undergoing complete pulmonary metastasectomy between January 2010 and December 2016. The impact of age, sex, extrapulmonary metastases, preoperative systemic therapy, number of metastases, laterality and largest diameter of metastasis on survival after metastasectomy was analysed.RESULTSA total of 29 male and 32 female patients were included in the study. The median follow-up time was 25.6 months. The mean number of resected metastases was 1.7 ± 1.1 (range 1–5). Ten patients had repetitive pulmonary metastasectomies. The median survival time was 31.3 months with a 2-year survival rate of 54%. Bilateral metastases or multiple nodules were not associated with a significantly decreased overall survival rate after metastasectomy. Shorter overall survival times were observed in male patients [hazard ratio (HR) 2.9, 95% confidence interval (CI) 1.42–5.92; P = 0.0035] and in patients with nodules larger than 2 cm (HR 3.18, 95% CI 1.45–6.98; P = 0.004). In multivariable analysis, both gender and tumour size remained significant independent prognostic factors.CONCLUSIONSExcellent overall survival rates after pulmonary metastasectomy for melanoma metastases were observed in patients with a metastatic diameter less than 2 cm and in female patients. In view of improved long-term outcome due to novel treatment options, the selection of patients for pulmonary metastasectomy based on prognostic factors will become increasingly important.

The Impact of Radiation-induced Up-regulations of IFN-γ on Local Tumor Control of Malignant Melanoma In Vivo

2012 ◽  
Vol 84 (3) ◽  
pp. S671-S672
Author(s):  
H. Ishikawa ◽  
Y. Yoshida ◽  
Y. Mutoh ◽  
S.K. Metcalfe ◽  
M. Zhang ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Local Tumor Control ◽  
Tumor Control ◽  
Local Tumor ◽  
Radiation Induced ◽  
Ifn Γ ◽  
The Impact

The impact of gender on the outcome of malignant melanoma: Overview of seven EORTC phase III trials.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 8523-8523
Author(s):  
A. Joosse ◽  
S. Collette ◽  
S. Suciu ◽  
E. de Vries ◽  
T. Nijsten ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Iii ◽  
Phase Iii Trials ◽  
The Impact

Lack of evidence to support large-panel genomic testing in treatment selection for malignant melanoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e22027-e22027
Author(s):  
Maya Dimitrova ◽  
Min Jae Kim ◽  
Douglas M. Donnelly ◽  
Keith M. Giles ◽  
Una Moran ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Clinical Decision Making ◽  
Treatment Selection ◽  
Genomic Profiling ◽  
First Line ◽  
Panel Size ◽  
Mutational Status ◽  
Significant Difference ◽  
Large Panel ◽  
The Impact

e22027 Background: Genomic profiling informs clinical decision-making for malignant melanoma (MM) as specific tumor mutations can be treated with targeted therapy (TT). However, given the range of different panel sizes available and increasing use of immune checkpoint inhibitors (ICI), the clinical significance of upfront, large-panel genomic profiling in MM remains undetermined. Herein, we investigate the impact of panel size and targetable mutational status on first-line treatment selection and outcomes of MM patients from 9 different institutions. Methods: We analyzed data for 1,341 MM patients from 3 cohorts. Cohort 1 included 169 patients enrolled at NYULH and profiled with the 50 gene Ion Torrent panel (IT). Cohort 2 included 256 patients enrolled at MSKCC, profiled with the 400-gene MSK-IMPACT panel (MSK-I). Cohort 3 included 916 patients enrolled at 7 different sites, profiled with whole exome sequencing (WES). Data for cohorts 2 and 3 were extrapolated from publicly available data using cBioPortal. We tested associations between molecular data, treatment choice and overall survival (OS), adjusting for baseline characteristics when available. Results: Treatment information was available for 100%, 25%, and 0% of patients in cohort 1, 2 and 3, respectively. Stage was available for all of cohort 1 (III, n = 68; IV, n = 101) and cohort 2 (III, n = 2; IV, n = 254), but in only 23% of cohort 3 (III, n = 184; IV n = 25). For the IT and MSK-I, BRAF and NRAS were among the top 5 most commonly mutated genes, whereas for WES only BRAF was in the top 5. In cohort 1, 36% (16/45) of BRAF MUT patients received first-line TT vs 25% (66/256) in cohort 2. There was no significant difference for BRAF MUT patients treated with ICI vs. TT in cohort 1 in OS (P = 0.19), nor for BRAF MUT patients from cohort 1 treated with ICI vs. those from cohort 2 treated with TT (OS P = 0.762). Conclusions: Publicly available datasets provide population-level data, however the heterogeneity and deficiency of reported clinical information limits their value and calls for data standardization. Without evidence of clear clinical benefit of a larger panel size, there is a rationale for adopting smaller, more cost effective panels in MM.

The Impact of Intradermal Lymphoscintigraphy on Surgical Management of Clinical Stage I Truncal Malignant Melanoma

1987 ◽  
Vol 13 (5) ◽  
pp. 508-515 ◽  
Author(s):  
ELISSA LIPCON KRAMER ◽  
JOSEPH J. SANGER ◽  
FREDERICK GOLOMB ◽  
ALFRED W. KOPF ◽  
ALLEN POSTEL
Keyword(s):  
Malignant Melanoma ◽  
Surgical Management ◽  
Clinical Stage ◽  
Stage I ◽  
The Impact

scholarly journals Landscape of Malignant Melanoma: The Impact of Upcoming Therapies

2017 ◽  
Vol 20 (9) ◽  
pp. A431
Author(s):  
MJ Bento ◽  
A Raimundo ◽  
J Sousa ◽  
F Valadas ◽  
FN Rocha-Gonçalves
Keyword(s):  
Malignant Melanoma ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document